Heart failure & cardiomyopathiesRandomised controlled trial
Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial
- Baseline characteristics report of the DECISION randomised controlled trial
- double-blind
- parallel-group
- placebo-controlled
Serum digoxin concentrations monitored during follow-up to achieve 0.5-0.9 ng/ml
Authors' conclusion
DECISION enrolled a contemporary and well-treated population of patients with HFrEF and HFmrEF
Study context
- Population
- Contemporary patients with heart failure (HF) and left ventricular ejection fraction (LVEF) ≤50% (HFrEF and HFmrEF)1,001 in full analysis set
- Participants
- 1,002 patients
- Comparison
- Low-dose digoxin vs placebo
- Primary endpoint
- Composite of:
- CV mortality
- Total HF hospitalisations
- Urgent HF hospital visits (trial endpoint; not reported)
Primary result
As reported in the abstract
Baseline characteristics · baseline
- Age, mean ± SD
- 73 ± 9 years
- Women
- 28%
- NYHA class II
- 88%
- LVEF, mean ± SD
- 33 ± 9%
- LVEF ≤40%
- 79%
- Sinus rhythm
- 71%
- AF
- 29%
- NT-proBNP, median [range as printed]
- 1404 pg/ml [930-2359]
- Beta-blockers
- 86%
- ACEi, ARB or ARNI
- 89%
- MRA
- 72%
- SGLT2 inhibitors
- 41%
- Loop diuretics
- 74%
Original publication
Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial. Eur J Heart Fail. Published 13 March 2026. doi:10.1093/ejhf/xuag073
Summarised from the published abstract; every number is checked against it